63264-29-9

Usage

Uses

Used in Pharmaceutical Research:
N2-Isobutyryl-2'-O-Methyl-guanosine is used as a building block in the synthesis of RNA molecules for research purposes, contributing to the development of novel therapeutic agents.
Used in Anticancer Applications:
N2-Isobutyryl-2'-O-Methyl-guanosine is studied for its potential anticancer activities, as the modifications to the guanosine nucleoside may confer unique properties that could be exploited in the treatment of cancer.
Used in Antiviral Applications:
N2-Isobutyryl-2'-O-Methyl-guanosine is also being investigated for its potential antiviral properties, with the isobutyryl and 2'-O-methyl modifications possibly enhancing its ability to target and inhibit viral replication.
Used in Biochemical Studies:
N2-Isobutyryl-2'-O-Methyl-guanosine serves as a useful tool in biochemical research, aiding in the understanding of nucleic acid structure and function, which is crucial for the advancement of molecular biology and biotechnology.

Upstream product

• 1336-21-6 ammonium hydroxide 
• 2140-71-8 2'-O-methylguanosine 
• 7732-18-5 water 
• 79-30-1 isobutyryl chloride 
• 97-72-3 2-Methylpropionic anhydride 
• 80791-87-3 2-amino-2'-O-methyladenosine 
• 2096-10-8 adenosine-2-amine 
• 194034-63-4 2,6-diamino-N²-isobutyryl-9-[3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-2'-O-methyl-β-D-ribofuranosyl]purine 
• 128219-75-0 2,6-diamino-9-[3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-2'-O-methyl-β-D-ribofuranosyl]purine 
• 87791-88-6 3′,5′-(1,1,3,3-tetraisopropyl-1,3-disiloxan-1,3-yl)-9-(β-D-ribofuranosyl)purin-2,6-diamine 
• 118-00-3 G 
• 126628-29-3 2-amino-9-((4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl)-1,9-dihydro-6H-purin-6-one 
• 958638-82-9 O⁶-[(2-trimethylsilyl)-ethyl]-2'-O-acetyl-3',5'-O-di-tert-butylsilanediyl guanosine 
• 958638-81-8 O⁶-[(2,4,6-tri-isopropyl)-benzenesulfonyl]-2'-O-acetyl-3',5'-O-di-tert-butylsilanediyl guanosine 

Downstream Products

• 114745-26-5 N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide 
• 1042664-46-9 5'-O-(tert-butyl)diphenylsilyl-2'-O-methyl-N²-isobutyrylguanosine 
• 199581-46-9 Thiocarbonic acid O-[(2R,3R,4R,5R)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(2-isobutyrylamino-6-oxo-1,6-dihydro-purin-9-yl)-4-methoxy-tetrahydro-furan-3-yl] ester O-(3-tert-butyl-phenyl) ester 
• 198703-58-1 N-(9-{(2R,3R,4R,5S)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-formyl-3-methoxy-tetrahydro-furan-2-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-isobutyramide 

Relevant academic research and scientific papers

2-O-Methyl-8-methylguanosine as a Z-Form RNA stabilizer for structural and functional study of Z-RNA

In contrast to Z-DNA that was stabilized and well-studied for its structure by chemical approaches, the stabilization and structural study of Z-RNA remains a challenge. In this study, we developed a Z-form RNA stabilizer m8Gm, and demonstrated that incorporation of m8Gm into RNA can markedly stabilize the Z-RNA at low salt conditions. Using the m8Gm-contained Z-RNA, we determined the structure of Z-RNA and investigated the interaction of protein and Z-RNA.

TRINUCLEOTIDE MRNA CAP ANALOGS

What is described is a trinucleotide cap analog comprising m7G(5′)p3-N1pN2 for increased efficiency of in vitro transcription of m7G(5′)p3-RNA, wherein m7G is N7-methylguanosine or analog, (5′)p3 is a 5′,5′-triphosphate bridge, and N1 or N2 or both ribonucleotide analogs linked to each other by a phosphate, p, and wherein the trinucleotide cap analog increases the efficiency of in vitro transcription.

Convenient synthesis of N2-isobutyryl-2′-O-methyl guanosine by efficient alkylation of O6-trimethylsilylethyl-3′,5′-di-tert-butylsilanediyl guanosine

We present a novel route for the synthesis of N2-isobutyryl-2′-O-methyl guanosine, introducing 3′,5′-di-tert-butylsilyl and O6-trimethylsilylethyl groups as efficient protections during the 2′-O-methylation step with NaH/CH3/su

Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives

The present invention provides methods for the chemical synthesis of nucleosides and derivatives thereof, including 2′-amino, 2′-N-phthaloyl, 2′-O-methyl, 2′-O-silyl, 2′OH nucleosides, C-nucleosides, nucleoside phosphoramidites, C-nucleoside phosphoramidites, and non-nucleoside derivatives.

Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives

The present invention provides methods for the chemical synthesis of nucleosides and derivatives thereof, including 2′-amino, 2′-N-phthaloyl, 2′-O-methyl, 2′-O-silyl, 2′-O-triisopropylsilyloxymethyl, 2′-OH nucleosides, C-nucleosides, nucleoside phosphoramidites, C-nucleoside phosphoramidites, and non-nucleoside derivatives.

Improved synthetic approaches toward 2'-O-methyl-adenosine and guanosine and their N-acyl derivatives

We developed several improved approaches toward 2'-O-methyl adenosine and guanosine and their N-acyl derivatives. (a) Transglycosylation of N4- acetyl-5', 3'-di-O-acetyl-2'-O-methyl cytidine with N6-Bz-adenine provided N6-benzoyl-5'3'-di-O-acetyl-2'-O-methyl adenosine in 50% yield. (b) Regioselective methylation of 2-amino-6-chloro purine riboside with MeI/NaH followed by hydrolysis provided 2'-O-Me-guanosine in high yield. The same 2'- O-Me-precursor was transformed into 2'-O-Me-adenosine in 58% yield. (c) Very efficient transformation of 2,6-diamino-purine riboside into N2-isobutyryl (isopropylphenoxyacetyl) 2'-O-Me-guanosine through methylation of 5',3'-O- TIPDSi derivative followed by selective N2-acylation, deamination and desylilation provided target compounds in 70% combined yield. (d) Mg2+ and Ag+ directed methylation of N1-Bzl-guanosine proceeded in >80% yield with ratio of 2'-O-Me-3'-O-Me=9:1. The same methylation of adenosine with Ag+ and Sr2+ acetylacetonates provided 2'-O-Me-adenosine in 75-80% yield. (C) 2000 Elsevier Science Ltd.

Process for the preparation of 2'-O-alkyl purine phosphoramidites

2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites are prepared by alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. Alkylation is effected on 2,6-diamino-9-(β-D-ribofuranosyl)purine followed by deamination to prepare guanosine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected on a dialkyl stannylene derivative of uridine to prepare uridine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on cytidine to prepare cytidine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on 2,6-diaminopurine to prepare 2,6-diaminopurine 2'-O-alkylated 3'-O-phosphormidites.